RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility features 2,176 high-performance GPUs across the US and Europe
The initial consideration for the transaction is US$ 12 million
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
Subscribe To Our Newsletter & Stay Updated
